Synopsis
Synopsis
0
JDMF
0
VMF
0
FDA Orange Book
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aequamen
2. Betahistin Al
3. Betahistin Ratiopharm
4. Betahistin Stada
5. Betahistin-ratiopharm
6. Betahistine
7. Betahistine Biphar
8. Betahistine Dihydrobromide
9. Betahistine Hydrochloride
10. Betahistine Mesylate
11. Betahistine Methanesulfonate
12. Betahistine Methanesulphonate
13. Betaserc
14. Betavert
15. By Vertin
16. By-vertin
17. Dihydrobromide, Betahistine
18. Dihydrochloride, Betahistine
19. Extovyl
20. Fidium
21. Hydrochloride, Betahistine
22. Lectil
23. Melopat
24. Mersilon
25. Mesylate, Betahistine
26. Methanesulfonate, Betahistine
27. Methanesulphonate, Betahistine
28. Pt 9
29. Pt-9
30. Pt9
31. Ribrain
32. Serc
33. Vasomotal
34. Vertigon
1. 5579-84-0
2. Betahistine Hydrochloride
3. Betahistine 2hcl
4. Betahistine Hcl
5. Serc
6. Betaserc
7. Microser
8. Antivom
9. 2-pyridineethanamine, N-methyl-, Dihydrochloride
10. Betahistine (dihydrochloride)
11. Pt-9
12. 2-(2-(methylamino)ethyl)pyridine Dihydrochloride
13. Betahistine Hydrochloride [usan:usp]
14. Beta-histine Dihdrochloride
15. N-methyl-n-(2-pyridin-2-ylethyl)amine Dihydrochloride
16. 5579-84-0 (hcl)
17. 49k58smz7u
18. Methyl[2-(2-pyridyl)ethyl]amine Dihydrochloride
19. N-methyl-2-pyridin-2-ylethanamine;dihydrochloride
20. Veserc
21. Mfcd00012813
22. N-methyl-2-(pyridin-2-yl)ethanamine Dihydrochloride
23. Nsc-757397
24. Methyl[2-(pyridin-2-yl)ethyl]amine Dihydrochloride
25. Novo-betahistine
26. Pt 9
27. Betahistine Hydrochloride [usan]
28. Einecs 226-966-5
29. Unii-49k58smz7u
30. Betahistine Dihcl
31. Betahistine Di Hcl
32. Serc (tn)
33. Beta-histine Dihydrochloride
34. N-methyl-2-pyridin-2-ylethanamine Dihydrochloride
35. Schembl60646
36. Spectrum1500670
37. Betahistine Hydrochloride ,(s)
38. Betahistine Hydrochloride (usp)
39. Chembl1446813
40. Hy-b0524a
41. Betahistine Dihydrochloride, 97%
42. Dtxsid10204355
43. Amy40800
44. Bcp13779
45. Ccg-40327
46. S3176
47. Akos015891507
48. Ks-5298
49. Nsc 757397
50. 2-(2-(methylamino)ethyl)pyridine 2hcl
51. Betahistine Dihydrochloride [mi]
52. Betahistine Hydrochloride [mart.]
53. Betahistine Hydrochloride [vandf]
54. Ncgc00095910-01
55. Betahistine Hydrochloride [usp-rs]
56. Betahistine Hydrochloride [who-dd]
57. Db-052800
58. Ft-0622911
59. Ft-0663076
60. Sw196969-3
61. En300-31560
62. 79b840
63. D03102
64. Betahistine Hydrochloride [usp Monograph]
65. A830811
66. Betahistine Dihydrochloride [ep Monograph]
67. N-methyl-2-(2-pyridinyl)ethanamine Dihydrochloride
68. N-methyl-2-(pyridin-2-yl)ethanaminedihydrochloride
69. N-methyl-2-pyridin-2-yl-ethanamine Dihydrochloride
70. Q27259291
71. Betahistine Dihydrochloride, European Pharmacopoeia (ep) Reference Standard
72. Betahistine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
| Molecular Weight | 209.11 g/mol |
|---|---|
| Molecular Formula | C8H14Cl2N2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 208.0534038 g/mol |
| Monoisotopic Mass | 208.0534038 g/mol |
| Topological Polar Surface Area | 24.9 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 83.3 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Histamine Agonists
Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (See all compounds classified as Histamine Agonists.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Betahistine Dihydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Betahistine Dihydrochloride manufacturer or Betahistine Dihydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betahistine Dihydrochloride manufacturer or Betahistine Dihydrochloride supplier.
PharmaCompass also assists you with knowing the Betahistine Dihydrochloride API Price utilized in the formulation of products. Betahistine Dihydrochloride API Price is not always fixed or binding as the Betahistine Dihydrochloride Price is obtained through a variety of data sources. The Betahistine Dihydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Novo-Betahistine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Novo-Betahistine, including repackagers and relabelers. The FDA regulates Novo-Betahistine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Novo-Betahistine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Novo-Betahistine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Novo-Betahistine supplier is an individual or a company that provides Novo-Betahistine active pharmaceutical ingredient (API) or Novo-Betahistine finished formulations upon request. The Novo-Betahistine suppliers may include Novo-Betahistine API manufacturers, exporters, distributors and traders.
click here to find a list of Novo-Betahistine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Novo-Betahistine DMF (Drug Master File) is a document detailing the whole manufacturing process of Novo-Betahistine active pharmaceutical ingredient (API) in detail. Different forms of Novo-Betahistine DMFs exist exist since differing nations have different regulations, such as Novo-Betahistine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Novo-Betahistine DMF submitted to regulatory agencies in the US is known as a USDMF. Novo-Betahistine USDMF includes data on Novo-Betahistine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Novo-Betahistine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Novo-Betahistine suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Novo-Betahistine Drug Master File in Korea (Novo-Betahistine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Novo-Betahistine. The MFDS reviews the Novo-Betahistine KDMF as part of the drug registration process and uses the information provided in the Novo-Betahistine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Novo-Betahistine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Novo-Betahistine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Novo-Betahistine suppliers with KDMF on PharmaCompass.
A Novo-Betahistine CEP of the European Pharmacopoeia monograph is often referred to as a Novo-Betahistine Certificate of Suitability (COS). The purpose of a Novo-Betahistine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Novo-Betahistine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Novo-Betahistine to their clients by showing that a Novo-Betahistine CEP has been issued for it. The manufacturer submits a Novo-Betahistine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Novo-Betahistine CEP holder for the record. Additionally, the data presented in the Novo-Betahistine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Novo-Betahistine DMF.
A Novo-Betahistine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Novo-Betahistine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Novo-Betahistine suppliers with CEP (COS) on PharmaCompass.
A Novo-Betahistine written confirmation (Novo-Betahistine WC) is an official document issued by a regulatory agency to a Novo-Betahistine manufacturer, verifying that the manufacturing facility of a Novo-Betahistine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Novo-Betahistine APIs or Novo-Betahistine finished pharmaceutical products to another nation, regulatory agencies frequently require a Novo-Betahistine WC (written confirmation) as part of the regulatory process.
click here to find a list of Novo-Betahistine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Novo-Betahistine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Novo-Betahistine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Novo-Betahistine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Novo-Betahistine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Novo-Betahistine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Novo-Betahistine suppliers with NDC on PharmaCompass.
Novo-Betahistine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Novo-Betahistine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Novo-Betahistine GMP manufacturer or Novo-Betahistine GMP API supplier for your needs.
A Novo-Betahistine CoA (Certificate of Analysis) is a formal document that attests to Novo-Betahistine's compliance with Novo-Betahistine specifications and serves as a tool for batch-level quality control.
Novo-Betahistine CoA mostly includes findings from lab analyses of a specific batch. For each Novo-Betahistine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Novo-Betahistine may be tested according to a variety of international standards, such as European Pharmacopoeia (Novo-Betahistine EP), Novo-Betahistine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Novo-Betahistine USP).
